Navigation Links
Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
Date:3/12/2008

nd multidisciplinary reach."

Recognizing that the atlases can exponentially advance the global understanding of many diseases and disorders that afflict millions, the Allen Institute has been successful in bringing diverse groups together to fund a common project by providing centralized databases of information that an individual researcher might spend a lifetime trying to gather.

"By putting our data in the hands of scientists studying devastating diseases and disorders such as autism, obesity, epilepsy, schizophrenia and Amyotrophic Lateral Sclerosis (ALS), these new projects will enable the work of many researchers, industries and organizations," said Elaine Jones, Chief Operating Officer at the Allen Institute. "We believe that free access to our unique resources is the best way to encourage widespread use and collaboration, which ultimately could expedite progress toward life-changing medical breakthroughs."

Mapping the Human Brain

Building on new technology and information gained in the development of its inaugural project, the ABA-Mouse Brain, which was completed in 2006, the Institute will develop the ABA-Human Brain, the world's first human brain atlas that overlays information about gene activity onto a three-dimensional anatomic map. For the first time and using a fresh approach to human brain mapping, the Institute will create a unique resource for understanding genes at work in the human brain and combining information about gene activity with existing anatomic and functional knowledge.

Currently, about 26 percent of American adults -- close to 58 million people -- suffer from a diagnosable mental disorder in a given year. This atlas will enable researchers and clinicians worldwide to advance understanding of brain diseases and disorders and speed progress toward breakthrough therapies.

"Ultimately, understanding the anatomic basis of gene expression in the normal brain will enable us to more effectively target
'/>"/>

SOURCE Allen Institute for Brain Science
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers
6. Triage study challenges notions of emergency medical response to disaster
7. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
8. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
9. Beyond DTC: Pharma Industry Faces New Challenges, Competition, Strategies for Market Dominance
10. White Paper Details Infection Control Challenges Hospitals Must Address During Construction
11. Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
(Date:5/20/2015)... 2015  Select Medical Corporation ("Select") (NYSE: ... granted early termination of the waiting period under ... as amended, applicable to the acquisition of Concentra ... venture that Select has created with Welsh, Carson, ... announced, MJ Acquisition Corporation has signed a definitive ...
(Date:5/20/2015)... May 20, 2015  Haemonetics Corporation (NYSE: HAE ... & CEO, will present at The Jefferies 2015 Global ... on June 1 st , 2015 at 8:30am Eastern ... Concannon,s presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Nanotechnologies, Inc. ("Shrink") (OTC Markets: INKN), an innovative high ... binding letter of intent to acquire 100% of Hawaii-based ... with global distribution for its award-winning suites of life ... Shrink will exchange 25,750,000 shares of ...
... 11, 2011 Dyadic International, Inc. ("Dyadic") (OTC ... the discovery, development, manufacture and sale of enzyme ... and biopharmaceutical industries, today announced that its President ... at the Advanced Biofuels Leadership Conference taking place ...
... advancements of our electronic age rests on our ability ... to point B, through circuitry. Doing so requires particular ... solar cells, and that task falls to semiconductors. ... schools of Engineering and Applied Science and Arts and ...
Cached Biology Technology:Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2Penn research advances understanding of lead selenide nanowires 2Penn research advances understanding of lead selenide nanowires 3
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... A University of California, Davis, microbiologist and a professional ... microbes to the International Space Station and study their ... Nov. 29 as winners of the International Space Station ... The team is led by Professor Jonathan Eisen ...
... 7. Dezember 2012 /PRNewswire/ -- Integrated Biometrics, LLC ... neuesten Fingerabdrucktechnologie einen weiteren technologischen Durchbruch bekannt. ... Produkt unter Verwendung der LES-Technologie (Light Emitting ... Film Transistor, TFT) her. Die LES-Technologie verwendet ...
... new plant-parasitic nematode worm ( Meloidoderita salina ) ... Michel Bay (MSMB) in France, where its abbey is a ... soil and is derived from the Latin word ,sal, or ... open source scientific journal ZooKeys . ...
Cached Biology News:Cheering microbes into space 2Integrated Biometrics stellt Sherlock vor - die weltweit leichtesten, dünnsten und kleinsten Appendix F Mobile ID-Fingerabdrucksensoren 2A pattern given by nature 2
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
...
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: